Kobe University Repository : Kernel タイトル Title 著者 Author(s) 掲載誌 巻号 ページ Citation 刊行日 Issue date 資源タイプ Resource Type 版区分 Resource Version 権利 Rights DOI JaLCDOI URL グローバル市場における後発医薬品との競争 : 内資系大手製薬企業 4 社の事例研究 (Competition with Generic Drugs in the Global Market : A Case Study of Four Large Japanese Pharmaceutical Companies) 島田, 智明 / 瓜生原, 葉子 国民経済雑誌,201(3):95-112 2010-03 Departmental Bulletin Paper / 紀要論文 publisher http://www.lib.kobe-u.ac.jp/handle_kernel/81006922 PDF issue: 2018-12-03
NEEDS IMS Health, 2009d
OTC IMS Health, 2009b
IMS
ARB ARB IMS Health, 2009c ARB ARB ARB HCTZ ARB CCB HCT ARB HCTZ CCB DPC Diagnosis Procedure Combination
ARB http://www. federalreserve.gov/releases/g5a/ BRICs Brazil, Russia, India, and China BRICs Pharmeging CAGR Compound Annual Growth Rate; Hill & Chui, 2009 IMS Health, MIDAS, Market Segmentation, MAT June 2008
NEEDS NEEDS NEEDS
IMS Health, 2009a
JT NEEDS
http://www.federalreserve.gov/releases/g5a/ IMS Health, MIDAS, Market Segmentation, MAT June 2008, Hill & Chui, 2009
USA 23,087 USA 26,898 USA 17,482 GlaxoSmith Klein 23,378 Pfizer 25,518 Pfizer 28,288 Glaxo Wellcome 13,082 Glaxo Wellcome 13,305 Aventis 15,446 Pfizer 22,567 GlaxoSmith Klein 24,935 GlaxoSmith Klein 26,858 Novartis 12,926 Novartis 12,994 AstraZeneca 15,420 USA 20,223 USA 21,347 USA 21,631 Bristol-Myers Squibb 11,283 Bristol-Myers Squibb 12,631 Pfizer 14,859 AstraZeneca 15,698 Bristol-Myers Squibb 19,423 AstraZeneca 17,343 Pfizer 10,689 Pfizer 12,230 Bristol-Myers Squibb 14,309 Aventis 14,899 Abbott 15,972 Abbott 17,268 American Home Products 8,669 Smith Kline Beecham 11,697 Glaxo Wellcome 13,827 Bristol-Myers Squibb 12,897 AstraZeneca 15,876 17,151 Roche 6,413 American Home Products 11,076 Novartis 13,229 Pharmacia 12,645 Aventis 15,780 Aventis 16,595 Hoechst Marion Roussel 8,076 Roche 9,914 Roche 11,449 11,954 14,851 Novartis 15,263 Bayer 7,882 Eli Lilly 9,236 Pharmacia 11,177 Novartis 11,567 Pharmacia 13,837 Bristol-Myers Squibb 14,705 7,696 8,562 10,694 Abbott 11,318 Novartis 13,381 Pharmacia 13,993 Pfizer 43,590 Pfizer 46,133 Pfizer 44,284 Pfizer 45,083 Pfizer 44,424 Pfizer 44,174 GlaxoSmith Klein 29,805 GlaxoSmith Klein 31,408 GlaxoSmith Klein 33,970 GlaxoSmith Klein 36,996 GlaxoSmith Klein 38,499 Sanofi- Aventis 40,597 USA 24,486 22,128 31,400 35,593 Sanofi- Aventis Sanofi- Aventis Sanofi- Aventis 38,394 GlaxoSmith Klein 37,797 19,517 USA 21,494 AstraZeneca 23,950 Novartis 29,491 Novartis 32,646 Novartis 35,647 Abbott 19,158 AstraZeneca 21,426 22,322 Roche 26,554 Roche 30,642 Roche 33,248 AstraZeneca 18,849 Novartis 18,497 Roche 21,898 AstraZeneca 26,475 AstraZeneca 29,559 AstraZeneca 31,601 Aventis 17,067 Sanofi- Aventis 17,830 USA 20,262 23,267 24,866 24,567 Novartis 16,020 Roche 17,447 Novartis 15,321 USA 22,080 USA 23,939 USA 23,850 Roche 15,964 Bristol-Myers Squibb 15,482 Wyeth 15,254 Wyeth 16,884 Wyeth 18,622 Eli Lilly 19,369 Bristol-Myers Squibb 14,925 Wyeth 13,964 Bristol-Myers Squibb 15,105 Eli Lilly 14,816 Eli Lilly 17,638 Wyeth 19,025 Data Book http://www. federalreserve.gov/releases/g5a/
MR Medical Representative; MR
BRICs Hill & Chui, 2009
BRICs SYR322 TAK375 AMG706 YM178 DU176b U3 MGI AkaRx
100 mg 500 m 250 mg 100 mg, 500 mg, PKPD 100 mg 100 mg 500 mg 500 mg 500 mg MGI
EBEWE
vs vs Hill, R., & Chui, M. 2009 The Pharmerging Future, Pharmaceutical Executive, Vol. 29, No. 7, pp. 4452. IMS Health 2009a Top 15 Global Corporations, http://www.imshealth.com/deployedfiles/imshealth/global/content/staticfile/top_line_data/global- Top_15_Companies.pdf. IMS Health 2009b Top 15 Global Products, http://www.imshealth.com/deployedfiles/imshealth/global/content/staticfile/top_line_data/global_ Top_15_Products.pdf.
IMS Health 2009c Top 15 Global Therapeutic Classes, http://www.imshealth.com/deployedfiles/imshealth/global/content/staticfile/top_line_data/global_ Top_15_Therapy_Classes.pdf. IMS Health 2009d Total Unaudited and Audited Global Pharmaceutical Market by Region, http://www.imshealth.com/deployedfiles/imshealth/global/content/staticfile/top_line_data/global_ Pharm_Market_by_Region.pdf. Data Book 2009